Stockscreener 앱 받기
8.07
3.73%
0.29
시간 외 거래:
8.01
-0.06
-0.74%
전일 마감가:
$7.78
열려 있는:
$7.79
하루 거래량:
638.02K
Relative Volume:
4.77
시가총액:
$349.22M
수익:
-
순이익/손실:
$-293.42M
주가수익비율:
-0.3011
EPS:
-26.8031
순현금흐름:
$-13.51M
1주 성능:
+4.94%
1개월 성능:
+27.29%
6개월 성능:
+297.54%
1년 성능:
+376.11%
1일 변동 폭
$7.71
$8.3828
1주일 범위
$7.555
$8.80
52주 변동 폭
$1.15
$12.46
미네르바 뉴로사이언스 Stock (NERV) Company Profile
명칭
Minerva Neurosciences Inc
전화
617-600-7373
주소
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
8.07 | 336.67M | 0 | -293.42M | -13.51M | -26.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 개시 | BTIG Research | Buy |
| 2019-10-02 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-25 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-31 | 개시 | H.C. Wainwright | Buy |
| 2017-09-01 | 개시 | Citigroup | Buy |
| 2017-03-06 | 재개 | Jefferies | Buy |
| 2016-05-12 | 재개 | Jefferies | Buy |
모두보기
미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - Stock Titan
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan
Minerva Neurosciences, Inc (NERV) Reports Q4 Earnings - AlphaStreet
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and Statistics - IndexBox
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
BRIEF-Minerva Neurosciences Q4 Net Income USD -283.668 Million - TradingView
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
[144] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Biotech CEO to present CNS disorder therapies at Miami conference - Stock Titan
Fed Meeting: Can Minerva Neurosciences Inc continue delivering strong returnsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen - MarketBeat
Is Minerva Neurosciences Inc. in a consolidation phaseMarket Weekly Review & Risk Controlled Swing Alerts - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
Weekly Earnings: Can Minerva Neurosciences Inc be recession proofTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. stock showing strong momentumGold Moves & Fast Moving Trade Plans - mfd.ru
Balyasny Asset Management L.P. Acquires Significant Stake in Min - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Minerva Neurosciences Inc. - GuruFocus
Minerva Neurosciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Coastlands (NASDAQ: NERV) reports 9.99% stake via convertible preferred/warrants - Stock Titan
Is Minerva Neurosciences Inc. in a long term uptrendTake Profit & Safe Entry Zone Tips - mfd.ru
Aug Swings: What drives MODVs stock priceJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Balyasny discloses 4.33M-share Minerva Neurosciences (NERV) position - Stock Titan
Is Minerva Neurosciences Inc. stock attractive for growth ETFs2025 Growth vs Value & Accurate Buy Signal Notifications - mfd.ru
Minerva Neurosciences (NERV) to Release Earnings on Tuesday - MarketBeat
Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance
Will Minerva Neurosciences Inc. (4MNA) stock see valuation expansionWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Minerva Neurosciences Expands Board Amid Fundraising Effort - MSN
Market Wrap: Can Minerva Neurosciences Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
How Minerva Neurosciences Inc. (4MNA) stock valuation compares with sectorWeekly Investment Summary & Scalable Portfolio Growth Methods - mfd.ru
미네르바 뉴로사이언스 (NERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):